Caplin Point gets approval for sterile injectables from Colombia

Nidhi Jani
/ Categories: Trending
Caplin Point gets approval for sterile injectables from Colombia

Caplin Point today informed the bourses that it has received Colombia's INVIMA approval for its small volume sterile injectable division at Puducherry.

The site inspection of the company’s Unit 1 was completed on May 10. The company has been found compliant as per INVIMA's norms of Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP).

The company is hoping that this approval would help to further expand its footprints in Latin America. The company’s Unit 1 is currently catering to emerging markets of Latin America and Africa with a variety of dosage forms such as tablets, capsules, softgel capsules, suppositories, liquid orals and topicals.

Caplin Point Laboratories is majorly engaged in the manufacturing of a wide range of ointments, creams and other external application preparations in addition to the regular segments of pharmaceutical formulations.

On Monday, the stock of Caplin Point Laboratories opened at Rs. 333.05 and made an intra-day high of Rs 335.25 and finally closed at Rs. 330 on the BSE. The stock had hit its 52-week high of Rs 612.90 on May 28, 2018 and 52-week low of Rs. 304.75 on January 29, 2019 on the BSE.

Rate this article:
5.0

Leave a comment

Add comment

DSIJ MINDSHARE

Mkt Commentary28-Mar, 2024

IPO Analysis29-Mar, 2024

Expert Speak29-Mar, 2024

Mindshare29-Mar, 2024

Multibaggers28-Mar, 2024

Knowledge

General26-Mar, 2024

MF25-Mar, 2024

General18-Mar, 2024

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR